Abstract: Myelin oligodendrocyte glycoprotein (MOG) antibody disease is a rare autoimmune disorder with antibodies against the MOG predominantly involving the optic nerve and spinal cord leading to vision loss and paralysis. When MOG antibody disease involves the brain, the phenotype is similar to acute disseminated encephalomyelitis (ADEM). In this review, we discuss MOG-positive cases presenting with encephalitis, encephalopathy, or ADEM-like presentation based on recently published series.
Introduction
Myelin oligodendrocyte glycoprotein (MOG) antibody disease refers to a relatively new spectrum of autoimmune disorders with antibodies against the MOG predominantly involving the optic nerve and spinal cord leading to vision loss and paralysis. 1, 2 Clinically, MOG antibody disease bears resemblance to neuromyelitis optica spectrum disorder (NMOSD) in the localization of inflammatory attacks within the central nervous system (CNS). It accounts for up to 40% of NMOSD patients who are seronegative for the aquaporin-4 (AQP4) antibody. 2, 3 However, unlike AQP4 which is an astrocytic protein, MOG is expressed on the outer surface of CNS myelin sheaths and oligodendrocyte processes. 2, 4 Thus, immunemediated attacks against MOG appear to be more demyelinating compared with AQP4 NMOSD; therefore, MOG is closer to multiple sclerosis (MS) in terms of its immunopathological features. 2, 5 When MOG antibody disease involves the brain, the phenotype is similar to acute disseminated encephalomyelitis (ADEM) with alterations in mental status and good outcomes after treatment with corticosteroids and intravenous immunoglobulins (IVIGs).
Many cases of MOG encephalitis were likely to be previously diagnosed as ADEM or recurrent ADEM, but with widespread availability of MOG antibody testing since 2015, several case series and reports have since been published on cases of encephalitis associated with MOG antibody (Table 1) . [6] [7] [8] [9] [10] [11] These studies contribute to the emerging view that ADEM may be stratified by transient or sustained MOG antibody seropositivity versus seronegative disease with distinct immunopathological processes. Clinically, classical ADEM and MOG antibody encephalitis present in a similar way, although classical ADEM is more likely to include myelitis and/or optic neuritis at onset. Radiologically, classical ADEM is characterized by the confluent widespread lesions of white and gray matter (GM), while MOG antibody encephalitis lesions tend to be more well-defined, cortically based or even absent altogether. 12 Moreover, the diagnosis of ADEM has only been established in the pediatric population. 13 In this review, we will focus on encephalitis presentations in both children and adults associated with the MOG antibody.
Epidemiology
Recent data suggest that MOG antibody disease is generally a condition of younger Caucasians with less female predominance than other autoimmune diseases of the CNS. 2, 14, 15 This is different from AQP4 NMOSD in which the average age of onset is in the late-30s/early-40s, race is over-represented by nonCaucasians, and females dominate up to 9:1. [16] [17] [18] [19] [20] MS patients are slightly older than MOG patients on average and share the propensity for Caucasian descent, but women with MS outnumber men by 3:1. 21 As described below, the epidemiology of the MOG antibody disease with presentations of encephalitis/ encephalopathy appears to mirror the overall MOG antibody population in each country, but the number of cases is too few to be conclusive.
In a Chinese study published in 2018, 20.7% of MOGpositive patients had a typical presentation of encephalitis at some point in their disease course. Number of men was 10 and the number of women was 8; the median age of onset was 22 years. In a related Chinese cohort of AQP4 seropositive NMOSD patients, only 3.6% of patients experienced an attack of encephalitis, all of whom were females in their late 30s. 7 In a small Japanese cohort of four cases with MOG antibody encephalitis, all were male with a median age of 37 years. 8 A second Japanese case series studied MOG seropositivity in 17 children presenting with inflammatory demyelinating diseases. 10 Nine patients tested positive for MOG, of whom five patients received an initial diagnosis of ADEM, encephalitis or meningitis. Four were men with only one female. 10 A UK study of five patients presenting with seizures as a manifestation of MOG seropositivity included three men and two women, with an average age of onset of 20 years (median: 10 years). 22 In a second UK study, 18% of a larger cohort of MOG patients presented with an ADEM-like or encephalitis clinical picture. 23 Those patients with encephalitis were younger by an average of 19 years than MOG antibody disease patients who presented with optic neuritis or transverse myelitis, 46% of whom had a relapsing course. Whether the encephalitic phenotype in MOG disease is more likely in younger patients has been addressed in some other MOG studies. It was noted that MOG patients with younger age at onset were more likely to experience an ADEM-like encephalopathic picture. [24] [25] [26] In a French study published in 2018, 2.5% (5 out of 197) of MOG patients presented with encephalopathy, and an additional 2% presented with brain stem syndrome along with encephalopathy. 27 A case report of a 46-year-old MOG antibody seropositive patient who presented with paraparesis secondary to bifrontal cortical encephalitis and relapsed later with optic neuritis is an example of a slightly older patient than those reported in the other published series. 9 One interesting study described an overlap between N-methyl-D-aspartate (NMDA) receptor antibodies and CNS demyelinating diseases (including MOG). In that study, MOG antibodies were detected in 9/23 patients diagnosed with NMDA receptor encephalitis with prominent clinical and/or magnetic resonance imaging (MRI) findings compatible with MOG demyelination. 28 It is difficult to distinguish the contribution of NMDA receptor versus MOG antibodies to the encephalitis presentations. In a different study published a year later, NMDA receptor antibody was detected in only 1 of 336 patients with different demyelinating diseases. Of interest, 26 out of 51 ADEM patients tested positive for MOG antibodies. Their median age was 7 (2-52) years, with 51% being women. 29 
Clinical presentation
Encephalitis of any etiology typically presents with focal neurological deficits depending on lesion localization, along with global change in mental status. Encephalitis is rare in NMOSD and MS but pathognomonic in ADEM. When MOG attacks the brain, the presentation is more similar to ADEM, including changes in mental status as well as increased frequency of seizures.
In the UK series, seizures were observed more frequently in MOG-positive patients: 14.7% as opposed to 1% in the AQP4 antibody seropositive group. All experienced generalized seizures with one having an On the other hand, all 18 patients from the Chinese series had typical symptoms of encephalitis with decreased consciousness, headache, and behavioral changes; seizures were experienced in 9 of those patients. 7 Among the nine MOG Japanese patients reported by Hino-Fukuyo et al., 10 two presented with ADEM, one with encephalitis and two with meningitis. Among four Japanese MOG patients in a different series, two experienced disturbed sensorium and two had seizures. 8 The seizures were generalized convulsions with or without abnormal behavior or altered sensorium. 8 In a single case report of an adult Japanese MOG patient, focal with secondary generalized motor fits followed by weakness of both lower limbs, fatigue, and memory decline were the presenting symptoms. 9 In a case report of a 7-year-old Japanese boy, a cluster of partial seizures without a change in mental status occurred along with four relapses of optic neuritis through his disease course. 30 In a study comparing the features of ADEM between MOG-positive and MOG-negative pediatric populations, MOG patients were more likely to experience higher cerebrospinal fluid (CSF) cell count, longitudinally extensive transverse myelitis, relapsing disease course, and a complete resolution of their lesions. They were also less likely to show atypical features of brain MRI than their seronegative peers. 31 Age at disease onset has been reported to affect the clinical presentation among MOG seropositive patients. Younger patients at onset were more likely to present with encephalomyelitis, while older patients experienced optic neuritis. [24] [25] [26] 32 Disease course MOG antibody seropositivity had been previously associated with a monophasic disease course, especially in children with ADEM. [33] [34] [35] More recently, MOG seropositivity has been reported to follow a relapsing disease course, not only among adults but also in pediatric patients. 22, 24, 25, 34, 36, 37 Higher MOG antibody titers seem to predict a relapsing disease course, as does persistent seropositivity over time. 25, 27, 38, 39 In contrast, a decline in the antibody level may portend a monophasic course. 27 Although attacks can be severe at presentation, recovery is usually good, and long-term outcomes appear to be much better than AQP4 antibody seropositive NMOSD. 27, 33, 34, 40 In the Chinese study, 72.2% of MOG encephalitis patients had a relapsing disease course. Two-thirds presented with encephalitis relapse at disease onset, while one-third experienced optic neuritis attacks before presenting with encephalitis. 7 In a retrospective study including nine MOG positive Japanese patients with three of them diagnosed as ADEM at final follow up, two patients were monophasic, while the third experienced a relapsing course. 10 Among four Japanese patients in another MOG cohort, two had a relapsing disease course with optic neuritis, and the other two remained monophasic. 8 In the UK study, all MOG seropositive patients who experienced seizures and encephalopathy, experienced a relapsing disease course. 6 CSF examination CSF findings in MOG seropositive patients are similar to NMOSD with pleocytosis of predominantly lymphocytes, a normal or mildly elevated protein, and rare oligoclonal bands (OCBs) around the time of an attack. Whether that specifically applies to MOG encephalitis cases needs a dedicated study of such cases. The few studies found in literature confirm the same CSF findings. [6] [7] [8] [9] In the Chinese case series, 41.2% of patients had increased intracranial pressure during the attack of encephalitis, and 64.7% showed CSF pleocytosis. 7 In the United Kingdom, the average white cell count in CSF was 251 cells/µL, while the average in the Japanese study was 126 cells/µL. 6, 8 OCBs were detected in 20% and 25% of patients in the United Kingdom and China, respectively. 6,7 Interestingly, 2/5 and 5/15 patients in the same cohorts tested positive for NMDA receptor antibodies, which could suggest an overlap between the two clinical entities. 6, 7 MRI features MRI findings in MOG encephalomyelitis/encephalitis usually report an ADEM-like pattern with diffuse signal changes noted in the cortical grey matter (GM)/subcortical white matter (WM), deep WM and deep GM as seen on both T2-weighted and fluid-attenuated inversion recovery (FLAIR) images (Figure 1 ). Scattered linear and nodular enhancement is seen in active lesions with some demonstrating restricted diffusion in some cases. [6] [7] [8] [9] 11 Resolution or significant decrease in conspicuity of lesions on follow-up imaging is noted in the majority of cases, but there are exceptions (Figure 2 ).
In the French study, despite the fact that 9 of 197 patients presented with an ADEM-like clinical picture, no specific radiologic pattern could be identified to distinguish MOG antibody cases from non-MOG antibody cases, except that leptomeningeal enhancement and thalamic lesions were unique to MOGpositive cohort. 27 On T2 sequences, the deep WM of the brain was the location most frequently involved on initial abnormal brain MRI. Tumefactive, poorly demarcated lesions and cortical lesions were more commonly observed in MOG patients than AQP4 antibody seropositive patients.
In the UK study, MOG antibody seropositive patients were more likely to present with an MRI classified as ADEM (44%) as opposed to (0%) in the AQP4 antibody seropositive group. The majority of patients showed complete resolution of their lesions on follow up MRI. In 2016, a Chinese study reported a different finding, where an ADEM-like radiological picture was observed in both AQP4 and MOG antibody seropositive patients. The only remarkable feature in AQP4 patients was the lack of enhancement of their brain lesions which suggested an intact blood-brain barrier and probably different pathophysiology. 41 In 2015, a study in Austria, reported that an ADEMlike clinical picture was observed in one MOG antibody seropositive patient among 17 patients in its cohort and none of the 59 AQP4 antibody seropositive patients. 34 Despite the fact that most MOG seropositive patients showed abnormal MRIs, none of them fulfilled McDonald's MS criteria.
In the Japanese case series, all four patients who presented with generalized epileptic seizures with or without altered sensorium, showed unilateral cortical brain lesions on FLAIR images. Moreover, the pattern correlated with hyperperfusion on single-photon emission computed tomography (SPECT). These lesions were differentiated from seizure-induced lesions by their presence on FLAIR rather than diffusion-weighted image (DWI), the presence of CSF pleocytosis and the favorable clinical response to high-dose steroids. These clues suggested an inflammatory nature to these cortical lesions. 8
Treatment and outcome
Acute treatment with corticosteroids and/or plasma exchange or IVIG is the current standard of care for MOG antibody encephalitis. In the published case series, the majority of cases were treated with intravenous methylprednisolone followed by slow oral prednisone taper with full recovery, 8, 9 and some had extra treatment with IVIG 7,11 or plasmapheresis. 6 Most patients showed excellent response to treatment with full recovery, [6] [7] [8] 11 while other patients continued to have residual neurologic deficits as well as MRI changes. 6,9 MOG disease is a steroid-responsive condition with a tendency to relapse upon rapid withdrawal. A slow steroid taper with close monitoring is recommended when treating those patients. 37, 42 For patients having a relapsing course, long-term immunosuppressive treatment is used. Data on longterm treatment was reported in only one case series in the United Kingdom. Rituximab and mycophenolate mofetil were the most commonly employed agents. 6 Due to uncertainty about the risk of recurrence in patients with MOG antibody disease, especially among those whose convert from seropositive to seronegative, long-term treatment can be deferred. In the UK case series, three cases were started on mycophenolate mofetil, the first of whom was relapse-free for 2 years. Upon experiencing an optic neuritis attack, rituximab was initiated, and 17 months later, he remained in clinical remission. The second remained stable after 12 months of treatment, except for residual cognitive changes. And the third patient experienced no more events over 20 months of follow-up. 6
Conclusion
Encephalomyelitis/encephalitis is an emerging presentation among MOG seropositive populations. Encephalomyelitis seems to be associated with younger age at disease onset and may account for a subset of ADEM presentations. MOG testing is warranted at initial presentation with encephalopathy, and preventive treatment is recommended upon relapse. A relapsing disease course is predicted by higher antibody levels and persistent seropositivity. MOG antibody disease is a steroid-responsive condition, but long term prognosis in cases of MOG encephalitis/encephalomyelitis is still not clear.
The main limitation of this review is that it is based on the few published studies primarily targeting this type of presentation in the MOG antibody seropositive populations. Larger studies are needed to better characterize the epidemiological characteristics, longterm prognosis as well as the value of early treatment initiation.
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